Immunic Inc. buy D. Boral Capital - sharewise

Jan 7, 2025 · This prediction is currently active. With a performance of -3.90%, the BUY prediction by D__Boral_Capital is trending in the wrong direction. This prediction currently runs until …

90%
OFF

Immunic Inc. Buy D. Boral Capital - Sharewise

2 weeks from now

Jan 7, 2025 · This prediction is currently active. With a performance of -3.90%, the BUY prediction by D__Boral_Capital is trending in the wrong direction. This prediction currently runs until …

sharewise.com

$17.00
OFF

Immunic (NASDAQ:IMUX) Receives Buy Rating From D. Boral Capital

2 weeks from now

Jan 7, 2025 · D. Boral Capital reaffirmed a "buy" rating and set a $17.00 target price on shares of Immunic in a research report on Tuesday. ... Immunic, Inc, a biotechnology company, …

marketbeat.com

$1.10
OFF

Immunic (NASDAQ:IMUX) Given “Buy” Rating At D. Boral Capital

2 weeks from now

Jan 9, 2025 · IMUX stock opened at $1.10 on Tuesday. Immunic has a 1-year low of $0.97 and a 1-year high of $2.11. The business’s 50 day moving average is $1.14 and its 200-day moving …

etfdailynews.com

$1.10
OFF

Immunic (NASDAQ:IMUX) Earns “Buy” Rating From D. Boral Capital

2 weeks from now

Jan 9, 2025 · Shares of NASDAQ:IMUX opened at $1.10 on Tuesday. The firm has a market cap of $99.09 million, a price-to-earnings ratio of -0.89 and a beta of 1.88. Immunic has a 1 year …

defenseworld.net

62%
OFF

Immunic (IMUX) Stock Forecast And Price Target 2025 - MarketBeat

2 weeks from now

3 days ago · D. Boral Capital. 0 of 5 stars : Reiterated Rating: Buy Buy: $17.00 $17.00 +1,459.62%: 11/25/2024: ... 8 Wall Street equities research analysts have issued "buy," "hold," …

marketbeat.com

$17
OFF

D. Boral Capital Maintains Buy On Immunic, Maintains $17 Price …

2 weeks from now

Jan 7, 2025 · D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a B... Invest Saudi Market. Stocks; ETFs; REITs; U.S. Market. Stocks; ETFs; Options ... D. Boral …

sahmcapital.com

$17
OFF

D. Boral Capital Maintains Buy On Immunic, Maintains $17 Price

2 weeks from now

D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target. Benzinga · 4d ago. D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and …

webull.com

$100
OFF

D. Boral Capital Served As Co-Manager To ImmunityBio, Inc.

2 weeks from now

Dec 12, 2024 · D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering D. Boral Capital Thu, Dec 12, …

yahoo.com

$17
OFF

IMUX - Stock Quotes For IMUX Ent Holdg, NASDAQ: IMUX Stock

2 weeks from now

Immunic Is Maintained at Buy by D. Boral Capital. Dow Jones · 5d ago. D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target. Benzinga · 5d ago. ... Immunic, Inc. is a …

webull.com

$30
OFF

ImmunityBio: D. Boral Capital Maintains A 'Buy' Rating, The Target ...

2 weeks from now

D. Boral Capital: Maintains: Buy: Buy: $30: $30: 2024-10-23: EF Hutton: Initiates Coverage On: Buy--$30 $--[Recent Earning Results]Immunitybio posted the Q3 of its 2024 financial results …

ainvest.com

0%
OFF

D. Boral Capital Reaffirms "Buy" Rating For ImmunityBio

2 weeks from now

18 hours ago · Institutional investors have recently bought and sold shares of the company. Victory Capital Management Inc. lifted its stake in shares of ImmunityBio by 16.0% in the …

marketbeat.com

$30.00
OFF

D. Boral Capital Reiterates "Buy" Rating For ImmunityBio

2 weeks from now

Dec 20, 2024 · D. Boral Capital reiterated a "buy" rating and set a $30.00 price objective on shares of ImmunityBio in a research report on Friday. ... IBRX - Get Free Report) 's stock had …

marketbeat.com

FAQs about Immunic Inc. buy D. Boral Capital - sharewise Coupon?

Should you buy immunic (IMUX) stock?

Immunic (NASDAQ:IMUX – Get Free Report) ‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a research report issued on Tuesday, Benzinga reports. They currently have a $17.00 price target on the stock. Other analysts have also recently issued reports about the company. ...

Is immunic stock a buy?

On average, analysts rate Immunic stock as a buy. The average analyst rating for Immunic stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months. ...

What is the price target for immunic (IMUX)?

The highest price target for IMUX is $28.00, while the lowest price target for IMUX is $5.00. The average price target represents a forecasted upside of 982.57% from the current price of $1.09. Enter your email address to receive the latest news and analysts' ratings for Immunic and its competitors. ...

Who sold immunitybio shares?

All of the shares were sold by ImmunityBio. Before deducting the underwriting discount and offering expenses payable by ImmunityBio, ImmunityBio expects to receive gross proceeds of approximately $100.0 million, assuming no exercise of the underwriters’ option to purchase additional shares. ...

What percentage of immunic stock is owned by insiders?

In the past three months, Immunic insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,395.00 in company stock and sold $0.00 in company stock. Only 3.00% of the stock of Immunic is held by insiders. 51.82% of the stock of Immunic is held by institutions. ...

Does Virtu Financial LLC own immunic?

Virtu Financial LLC bought a new stake in Immunic during the 3rd quarter worth about $50,000. Jane Street Group LLC boosted its stake in shares of Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the last quarter. ...